Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
1 report, 1 independent
Updated Aug 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.